Samarth Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 29-06-2024
- Paid Up Capital ₹ 2.50 M
as on 29-06-2024
- Company Age 27 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.70 M
as on 29-06-2024
- Revenue %
(FY 2021)
- Net Worth 2.93%
(FY 2021)
- Total Assets 1.37%
(FY 2021)
About Samarth Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.70 M.
Pranav Shah and Rajiv Shah serve as directors at the Company.
- CIN/LLPIN
U99999MH1997PTC110616
- Company No.
110616
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Sep 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNa, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Samarth Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pranav Shah  | Director | 02-Jan-2020 | Current |
| Rajiv Shah | Director | 05-Sep-2014 | Current |
Financial Performance of Samarth Pharma.
Samarth Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth moved up by a moderate rise of 2.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Samarth Pharma?
In 2019, Samarth Pharma had a promoter holding of 0.12% and a public holding of 99.88%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Money Honey Financial Services Private LimitedActive 20 years 3 monthsPranav Shah and Rajiv Shah are mutual person
- Money Honey Consultants Private LimitedActive 16 years 3 months
Pranav Shah and Rajiv Shah are mutual person
Penang Enterprises Private LimitedActive 27 years 10 monthsPranav Shah and Rajiv Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Inida Creation Date: 21 Mar 2000 | ₹2.70 M | Open |
How Many Employees Work at Samarth Pharma?
Samarth Pharma has a workforce of 2 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Samarth Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Samarth Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
